Abstract: OBJECTIVE To provide foreign experience for the improvement of China's compassionate use system under the background that there is no specific medicine for patients with COVID-19. METHODS Studied the specific content of Canada's special access program through literature research methods and so on. RESULTS Canada has a relatively perfect system, which was worthy of our country's reference. CONCLUSION According to the specific national conditions of our country, compassionate use system should be improved from three dimensions:doctor, government and drug manufacturer.